Anamitra Bhaumik

Mr. Anamitra Bhaumik


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
BGBryan Correa Gonzalez
Bryan Correa Gonzalez
AKAkshaya Karthikeyan
Akshaya Karthikeyan
LMLove A. Moore
Love A. Moore
ABAnamitra Bhaumik
Anamitra Bhaumik
ESEthan Sandoval
Ethan Sandoval
ALAlan Paul Lombard
Alan Paul Lombard
Background/Objectives: Combinations of PARP inhibitors (PARPi) and androgen receptor pathway inhibitors (ARPi) have led to clinical success in treating advanced prostate cancer. However, it is unclear where in the clinical paradigm these combinations will fare best, and their mechanism of action remains unclear. We sought to address open questions and explore alternative strategies to enhance PARPi efficacy. Methods: Viability and morphology were assessed in response to (1) abiraterone, olaparib, or combination and (2) enzalutamide, talazoparib, or combination in castration-resistant C4-2B cells and abiraterone- or enzalutamide-resistant derivative cell models (ARPi-resistant). The efficacy of the ATM inhibitor lartesertib with and without a PARPi was also determined. Western blots and RNA-sequencing were used to interrogate the mechanistic effects of treatment. Results: PARPi and ARPi combinations were effective in all models but provided the most benefit in ARPi-sensitive C4-2B cells. Mechanistically, ARPi was not found to affect homologous recombination repair gene expression but may increase PARP activity. Prolonged PARP inhibition was found to increase the expression of AR target genes, and PARPi pre-treatment increased sensitivity to enzalutamide. ATM inhibition significantly increases PARPi efficacy and appears to outperform ARPi-containing combinations in ARPi-resistant models. Conclusions: PARPi and ARPi combinations are effective in ARPi-resistant models, but efficacy appears stronger in ARPi-sensitive CRPC cells. Presented findings support a novel hypothesis that PARP inhibition may increase ARPi sensitivity with increasing AR activity. Additionally, ATM inhibition may provide more benefit than an ARPi in combination with a PARPi in ARPi-resistant settings. These findings support continued PARPi development for improving patient outcomes.

23 July 2026 in Cancers
Verified
Journal Article
Open access
PDF file
BGBryan Correa Gonzalez
Bryan Correa Gonzalez
AKAkshaya Karthikeyan
Akshaya Karthikeyan
LMLove A. Moore
Love A. Moore
ABAnamitra Bhaumik
Anamitra Bhaumik
ESEthan Sandoval
Ethan Sandoval
ALAlan Paul Lombard
Alan Paul Lombard
Background/Objectives: Though PARP inhibition has improved the management of advanced prostate cancer, patient outcomes may be modest and disease progression on treatment is common. We sought to improve understanding of tumor cell response to PARP inhibition to support development of novel strategies to enhance and/or prolong PARP inhibitor (PARPi) efficacy. Methods: Cell viability assays and microscopy were used for initial characterization of PARPi response in models of advanced prostate cancer. RNA sequencing was performed to investigate time-dependent transcriptomic changes induced by PARP inhibition. Western blots, flow cytometry, and both additional viability assays and microscopy were used to validate RNA sequencing results and test potential therapeutic strategies. Results: Characterization of responses to PARP inhibition reveals time-dependent changes which may be targeted to improve treatment efficacy. In line with the expected PARPi mechanism of action, short-term treatment is largely associated with activation of ATM and the DNA damage response and cell cycle checkpoint signaling. Targeting ATM with clinical stage inhibitors significantly enhances reduction of tumor cell viability by PARP inhibition. Tumor cells exposed to longer-term treatment exhibit SLUG-dependent epithelial–mesenchymal transition (EMT) and evidence for altered fatty acid metabolism, both of which may be targeted to enhance PARPi anti-tumor cell effects. Conclusions: This study provides insight into both short and longer-term cellular response to PARPi treatment and provides a foundation for additional efforts to explore effective strategies to maximize the utility of PARP inhibition for managing prostate cancer.

16 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
BGBryan Correa Gonzalez
Bryan Correa Gonzalez
AKAkshaya Karthikeyan
Akshaya Karthikeyan
LMLove A. Moore
Love A. Moore
ABAnamitra Bhaumik
Anamitra Bhaumik
ESEthan Sandoval
Ethan Sandoval
ALAlan Paul Lombard
Alan Paul Lombard
Background/Objectives: Though PARP inhibition has improved the management of advanced prostate cancer, patient outcomes may be modest and progression on treatment is common. We sought to improve understanding of tumor cell response to PARP inhibition to support development of novel strategies to enhance and/or prolong PARP inhibitor (PARPi) efficacy. Methods: Cell viability assays and microscopy were used for initial characterization of PARPi response in models of advanced prostate cancer. RNA-sequencing was performed to investigate time-dependent transcriptomic changes induced by PARP inhibition. Western blots, flow cytometry, and both additional viability assays and microscopy were used to validate RNA-sequencing results and test potential therapeutic strategies. Results: Characterization of response to PARP inhibition reveals time-dependent changes which may be targeted to improve treatment efficacy. In line with expected PARPi mechanism of action, short-term treatment is largely associated with activation of ATM and the DNA damage response and cell cycle checkpoint signaling. Targeting ATM with clinical stage inhibitors significantly enhances reduction of tumor cell viability by PARP inhibition. Tumor cells exposed to longer-term treatment exhibit slug-dependent epithelial-mesenchymal transition (EMT) and evidence for altered fatty acid metabolism, both of which may be targeted to enhance PARPi anti-tumor cell effects. Conclusions: This study provides insight into both short and longer-term cellular response to PARPi treatment and provides a foundation for additional efforts to explore effective strategies to maximize the utility of PARP inhibition for managing prostate cancer.